Orexo AB (publ)

Orexo AB (publ) is a pharmaceutical company that provides advanced treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for opioid use disorder, Abstral for breakthrough pain in cancer patients, Edluar for insomnia, and Diabact UBT for the diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose, OX640 (powder-based epinephrine) for anaphylaxis, OX390 for overdoses caused by a combination of life-threatening illicit drugs, OX125 (powder-based nalmefene) for opioid overdose, and OX472 (intranasal semaglutide, a GLP-1 receptor agonist) using its proprietary AmorphOX technology, as well as thermostable and needle-free mucosal vaccines. Incorporated in 1994, Orexo AB (publ) is headquartered in Uppsala, Sweden.